JP2015520744A - ヒトの肺疾患および胃腸管系疾患の新規ケモカインマーカーであるｃｘｃｌ１７の使用 - Google Patents

ヒトの肺疾患および胃腸管系疾患の新規ケモカインマーカーであるｃｘｃｌ１７の使用 Download PDF

Info

Publication number
JP2015520744A
JP2015520744A JP2015510500A JP2015510500A JP2015520744A JP 2015520744 A JP2015520744 A JP 2015520744A JP 2015510500 A JP2015510500 A JP 2015510500A JP 2015510500 A JP2015510500 A JP 2015510500A JP 2015520744 A JP2015520744 A JP 2015520744A
Authority
JP
Japan
Prior art keywords
cxcl17
disease
cancer
tumor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015510500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520744A5 (enExample
Inventor
ズロトニク，アルバート
ブルクハルト，アマンダ，エム．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2015520744A publication Critical patent/JP2015520744A/ja
Publication of JP2015520744A5 publication Critical patent/JP2015520744A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
JP2015510500A 2012-05-03 2013-05-03 ヒトの肺疾患および胃腸管系疾患の新規ケモカインマーカーであるｃｘｃｌ１７の使用 Pending JP2015520744A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261642209P 2012-05-03 2012-05-03
US61/642,209 2012-05-03
PCT/US2013/039586 WO2013166470A2 (en) 2012-05-03 2013-05-03 Uses of cxcl17, a novel chemokine marker of human lung and gastrointestinal disease

Publications (2)

Publication Number Publication Date
JP2015520744A true JP2015520744A (ja) 2015-07-23
JP2015520744A5 JP2015520744A5 (enExample) 2016-11-24

Family

ID=49515050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015510500A Pending JP2015520744A (ja) 2012-05-03 2013-05-03 ヒトの肺疾患および胃腸管系疾患の新規ケモカインマーカーであるｃｘｃｌ１７の使用

Country Status (7)

Country Link
US (1) US20150140008A1 (enExample)
EP (1) EP2866832A4 (enExample)
JP (1) JP2015520744A (enExample)
AU (1) AU2013256050A1 (enExample)
CA (1) CA2871671A1 (enExample)
MX (1) MX2014013380A (enExample)
WO (1) WO2013166470A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925050A1 (en) * 2013-09-30 2015-04-02 The Regents Of The University Of California Identification of cxcr8, a novel chemokine receptor
US20210277102A1 (en) * 2016-08-30 2021-09-09 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating a tumor suppressor deficient cancer
TR201811691A2 (tr) * 2018-08-10 2018-09-21 Hacettepe Ueniversitesi Cxcl17 ami̇no ucu öncül di̇zi̇si̇nden türevlenen i̇mmünmodülatör pepti̇t
WO2025007057A2 (en) * 2023-06-29 2025-01-02 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte trafficking receptor and ligand

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506043A (ja) * 2002-04-12 2006-02-23 ファルマシア・コーポレイション 脈管形成に関与する異なって発現された遺伝子、それによりコードされる蛋白質、およびそれを用いる方法
JP2006507809A (ja) * 2002-08-19 2006-03-09 ファルマシア・コーポレーション Ｖｅｇｆ共調節ケモカイン−１発現のアンチセンス変調

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506043A (ja) * 2002-04-12 2006-02-23 ファルマシア・コーポレイション 脈管形成に関与する異なって発現された遺伝子、それによりコードされる蛋白質、およびそれを用いる方法
JP2006507809A (ja) * 2002-08-19 2006-03-09 ファルマシア・コーポレーション Ｖｅｇｆ共調節ケモカイン−１発現のアンチセンス変調

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ＡＣＴＡ ＢＩＯＣＨＩＭＩＣＡ ＥＴ ＢＩＯＰＨＹＳＩＣＡ ＳＩＮＩＣＡ, vol. Ｖｏｌ．４１，Ｎｏ．８, JPN6016049419, 2009, pages ｐ６３１−６３７ *
ＢＩＯＣＨＥＭＩＣＡＬ ＡＮＤ ＢＩＯＰＨＹＳＩＣＡＬ ＲＥＳＥＡＲＣＨ ＣＯＭＭＵＮＩＣＡＴＩＯＮ, vol. Ｖｏｌ．３５０，Ｎｏ．１, JPN6016049425, 2006, pages ｐ７４−８１ *
ＢＩＯＣＨＥＭＩＣＡＬ ＡＮＤ ＢＩＯＰＨＹＳＩＣＡＬ ＲＥＳＥＡＲＣＨ ＣＯＭＭＵＮＩＣＡＴＩＯＮ, vol. Ｖｏｌ．４２０，Ｎｏ．２, JPN6016049418, April 2012 (2012-04-01), pages ｐ３３６−３４２ *
ＧＡＳＴＲＯＥＮＴＥＲＯＬＯＧＹ, vol. Ｖｏｌ．１４０，Ｎｏ．１, JPN6016049417, 2011, pages ｐ３１０−３２１ *
ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ, vol. Ｖｏｌ．１０７，Ｎｏ．１, JPN6016049421, 2003, pages ｐ２２−２９ *
ＪＯＵＲＮＡＬ ＯＦ ＩＭＭＵＮＯＬＯＧＹ, vol. Ｖｏｌ．１７６，Ｎｏ．４, JPN6016049423, 2006, pages ｐ２０６９−２０７３ *

Also Published As

Publication number Publication date
EP2866832A4 (en) 2016-04-13
US20150140008A1 (en) 2015-05-21
EP2866832A2 (en) 2015-05-06
WO2013166470A2 (en) 2013-11-07
MX2014013380A (es) 2015-02-10
AU2013256050A1 (en) 2014-11-20
CA2871671A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
US11945875B2 (en) Motile sperm domain containing protein 2 and cancer
US12391766B2 (en) Antibodies against N-acetylglucosamine and N-acetyl-galactosamine
CN103459595B (zh) 针对人前列腺素e2受体ep4的抗体
CN103261412A (zh) 抗人ccr7 抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体
JP2016501843A (ja) 癌治療および判断ターゲットとしてのｌｙ７５
JP2011509079A (ja) エフリンａ型受容体１０タンパク質
EP3123173B1 (en) Compositions for suppressing cancer by inhibition of tmcc3
US20240166720A1 (en) Bioengineered immunomodulatory fusion protein compositions
JP2015520744A (ja) ヒトの肺疾患および胃腸管系疾患の新規ケモカインマーカーであるｃｘｃｌ１７の使用
US20220242964A1 (en) Compositions and methods for regulating erythropoiesis
EP2909236B1 (en) Methods and compositions for the treatment of pancreatic cancer
CN109476759B (zh) Prl3抗体
CN111378039B (zh) 治疗恶性肿瘤的抗体及其应用
CN114748627B (zh) 可溶性cd58在胰腺癌预防和治疗中的应用
WO2024036197A2 (en) Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome
WO2024036192A2 (en) Compositions and methods for assessing the severity of and treating covid-19
WO2025251615A1 (zh) 一种功能性p2x1膜蛋白单克隆抗体的制备方法及其应用
WO2023088429A1 (zh) SIRPα变体及其应用
JP2025503924A (ja) 抗ｂ７－ｈ３化合物及び使用方法
CN115068614A (zh) 用于诊断、治疗和预防癌症的方法和组合物
JPWO2015182121A1 (ja) アレルギー誘発性物質の検査、アレルギーの診断および治療
JP2012515544A (ja) Ｐｔａ０８９タンパク質
CN107604064A (zh) Ccl20在肿瘤化疗疗效评估和肿瘤治疗中的应用
US20090274696A1 (en) Methods for treating inflammation
Tian et al. Anti-DDR1 mAb Combined with PD-1 Blockade Enhances Gastric Cancer Immunotherapy by Activating CD8 T Cells and Suppressing the Col1-DDR1-ERK Pathway

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109